ChromaDex Corporation

Equities

CDXC

US1710774076

Biotechnology & Medical Research

Market Closed - Nasdaq 01:00:00 2024-07-03 pm EDT 5-day change 1st Jan Change
2.54 USD -1.55% Intraday chart for ChromaDex Corporation -4.15% +77.62%
LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
ChromaDex Joins Russell 2000 Index MT
ChromaDex Corporation(NasdaqCM:CDXC) added to Russell Small Cap Completeness Index CI
ChromaDex Corporation(NasdaqCM:CDXC) added to Russell 2000 Index CI
ChromaDex Corporation(NasdaqCM:CDXC) added to Russell 3000E Index CI
ChromaDex Corporation(NasdaqCM:CDXC) added to Russell 3000 Growth Index CI
ChromaDex Corporation(NasdaqCM:CDXC) added to Russell 3000E Growth Index CI
ChromaDex Corporation(NasdaqCM:CDXC) added to Russell 2000 Growth Index CI
ChromaDex Corporation(NasdaqCM:CDXC) added to Russell 2000 Dynamic Index CI
ChromaDex Corporation(NasdaqCM:CDXC) added to Russell 2500 Growth Index CI
ChromaDex Corporation(NasdaqCM:CDXC) added to Russell Small Cap Comp Growth Index CI
ChromaDex Corporation(NasdaqCM:CDXC) added to Russell 2500 Index CI
ChromaDex Corporation(NasdaqCM:CDXC) added to Russell 3000 Index CI
ChromaDex Chief Financial Officer Brianna Gerber to Resign MT
ChromaDex Says Nicotinamide Riboside Shows 'Promising Effects' in Peripheral Artery Disease Trial MT
ChromaDex Corp Shares Results from a Milestone Phase II Clinical Study Showing the Promising Effects of Nicotinamide Riboside (NR) Supplements for People with Peripheral Artery Disease CI
Chromadex to Launch Niagen+, the First-Of-Its-Kind Pharmaceutical-Grade Intravenous and Injectable Niagen® CI
Sector Update: Health Care Stocks Higher Late Afternoon MT
ChromaDex Says US FDA Grants NRC Orphan Drug, Rare Pediatric Disease Designations -- Shares Climb Pre-Bell MT
Transcript : ChromaDex Corporation, Q1 2024 Earnings Call, May 08, 2024
Earnings Flash (CDXC) CHROMADEX CORPORATION Reports Q1 Revenue $22.2M, vs. Street Est of $23.6M MT
ChromaDex Corporation Reiterates Earnings Guidance for the Full Year of 2024 CI
ChromaDex Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Chromadex Corp. Announces an Ingredient Partnership with Solgar CI
Chromadex Announces Inaugural Major Grocery Debut of Tru Niagen® At Sprouts Farmers Market CI
Roth MKM Raises Price Target on ChromaDex to $6 From $4.25, Keeps Buy Rating MT
Chart ChromaDex Corporation
More charts
Chromadex Corp. is a global bioscience company. The Company is engaged in research on nicotinamide adenine dinucleotide (NAD+), an essential coenzyme that is a key regulator of cellular metabolism and is found in every cell of the human body. Its segments include Consumer Products, Ingredients and Analytical Reference Standards and Services. The Consumer Products segment provides finished dietary supplement products that contain the Company's proprietary ingredients, commercialized as Tru Niagen, directly to consumers and distributors. The Ingredients segment develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. The Ingredients segment provides Niagen in ingredient form to its strategic partners. The Analytical Reference Standards and Services segment offers the supply of phytochemical reference standards and other research and development services.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
2.54 USD
Average target price
6.34 USD
Spread / Average Target
+149.61%
Consensus